Tempest Therapeutics, Inc. (TPST) Misses Q2 EPS by 2c

Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($0.54), $0.02 worse than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Cal-Maine pays $1.5M in egg price-fixing deal as executives face no charges
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M